SP
Sun Pharma Advanced Research Company Ltd (SPARC)
₹176.46
Mkt cap
₹5,727 Cr
P/E ratio
3.59
P/B
4.29
Div yield
0.00%
ROE
281.00%
ROCE
165.00%
EPS (TTM)
₹49.15
Book value
₹41
52W range
108–289
Sector
Healthcare
Price history
Previous close
Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products. [1]
NSE SPARCBSE 532872
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−38.94% from high₹176
₹108+63.39% from low₹289
Current
₹176.46
Prev close
₹182.98
Day
−3.56%
Price performance
1D
−3.54%
1W
+2.75%
1M
−15.49%
3M
−15.32%
6M
+18.81%
1Y
+33.72%
YTD
+30.02%
Financials
Revenue, profit & margin
P/E ratio
3.6×
SPARC is 90% below the sector median of 34.4×
SPARC3.6×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 24 | 21 | 14 | 17 | 17 | 13 | 15 | 27 | 10 | 8 | 8 | 1,853 | 40 | |
| Expenses | 126 | 113 | 116 | 124 | 112 | 117 | 89 | 81 | 62 | 74 | 65 | 80 | 74 | |
| Operating Profit | -102 | -91 | -103 | -108 | -95 | -104 | -74 | -54 | -52 | -66 | -57 | 1,773 | -34 | |
| OPM % | -427% | -432% | -740% | -649% | -566% | -808% | -499% | -198% | -543% | -838% | -673% | 96% | -86% | |
| Other Income | 10 | 8 | 6 | 4 | 2 | 0 | 0 | 0 | 9 | 0 | -12 | 2 | 24 | |
| Interest | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 5 | 6 | 8 | 9 | 12 | 8 | |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | |
| Profit before tax | -95 | -86 | -100 | -107 | -97 | -108 | -80 | -61 | -52 | -76 | -81 | 1,761 | -21 | |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
| Net Profit | -95 | -86 | -100 | -107 | -97 | -108 | -80 | -61 | -52 | -76 | -81 | 1,761 | -21 | |
| EPS in Rs | -2.94 | -2.66 | -3.07 | -3.29 | -2.98 | -3.32 | -2.46 | -1.88 | -1.60 | -2.34 | -2.48 | 54.26 | -0.65 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
2 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −2.73% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 10 Aug '26 |
| Earnings day | −2.73% |
| +1 day | −3.73% |
| +5 days | −7.43% |
| +15 days | −6.51% |
| +30 days | −7.15% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Sep 202665.68%Promoter
Promoters65.68%
FIIs3.74%0.16
DIIs0.11%0.02
Public30.48%0.14
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| SPARC | ₹176.46 | 3.59 | 5,727 | 0.00% | −21 | +59.68% | 40 | +314.11% | 164.99% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports15
Concall transcripts23
TranscriptJan 2026PPTJan 2026TranscriptDec 2024PPTDec 2024TranscriptApr 2024RECApr 2024TranscriptJan 2024TranscriptJan 2024PPTJan 2024PPTJan 2024TranscriptNov 2023PPTNov 2023TranscriptOct 2022PPTOct 2022TranscriptDec 2021PPTDec 2021PPTDec 2021PPTDec 2021PPTSep 2020PPTSep 2019PPTSep 2018PPTSep 2018PPTAug 2016
Credit ratings5
Announcements5
Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2026 22 Oct - Board meets on November 2, 2026, to approve Q2 and half-year FY2026-27 financial results.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 OctUpdate On Litigation - Intimation Under Regulation 30 Of SEBI (LODR), 2015 4 Oct - CESTAT upheld refund of CENVAT credit worth Rs. 2,751 lakhs; Revenue appeal dismissed.Closure of Trading Window 25 Sep - Trading window closes from October 1, 2026 until 48 hours after Q2 and half-year results.Filing Of Application For Reclassification With Stock Exchanges 13 Aug - SPARC filed application for promoter-group reclassification to public under Regulation 31A on August 13, 2026.